OPZELURA Drug Patent Profile

Which patents cover Opzelura, and when can generic versions of Opzelura launch?

Opzelura is a drug marketed by Incyte Corp and is included in one NDA. There are twenty-one patents protecting this drug and one Paragraph IV challenge.

This drug has three hundred and thirty-nine patent family members in forty-nine countries.

The generic ingredient in OPZELURA is ruxolitinib phosphate. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the ruxolitinib phosphate profile page.

DrugPatentWatch^® Generic Entry Outlook for Opzelura

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be May 20, 2031. This may change due to patent challenges or generic licensing.

There have been three patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for OPZELURA

International Patents:	339
US Patents:	21
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for OPZELURA

Paragraph IV (Patent) Challenges for OPZELURA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
OPZELURA	Cream	ruxolitinib phosphate	1.5%	215309	1	2023-07-31

US Patents and Regulatory Information for OPZELURA

OPZELURA is protected by twenty-two US patents and three FDA Regulatory Exclusivities.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Incyte Corp	OPZELURA	ruxolitinib phosphate	CREAM;TOPICAL	215309-001	Sep 21, 2021		RX	Yes	Yes
Incyte Corp	OPZELURA	ruxolitinib phosphate	CREAM;TOPICAL	215309-001	Sep 21, 2021		RX	Yes	Yes					Y
Incyte Corp	OPZELURA	ruxolitinib phosphate	CREAM;TOPICAL	215309-001	Sep 21, 2021		RX	Yes	Yes
Incyte Corp	OPZELURA	ruxolitinib phosphate	CREAM;TOPICAL	215309-001	Sep 21, 2021		RX	Yes	Yes
Incyte Corp	OPZELURA	ruxolitinib phosphate	CREAM;TOPICAL	215309-001	Sep 21, 2021		RX	Yes	Yes					Y
Incyte Corp	OPZELURA	ruxolitinib phosphate	CREAM;TOPICAL	215309-001	Sep 21, 2021		RX	Yes	Yes					Y
Incyte Corp	OPZELURA	ruxolitinib phosphate	CREAM;TOPICAL	215309-001	Sep 21, 2021		RX	Yes	Yes			Y

International Patents for OPZELURA

When does loss-of-exclusivity occur for OPZELURA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Costa Rica

Croatia

Cyprus

Denmark

Ecuador

Eurasian Patent Organization

European Patent Office

Hong Kong

Hungary

Israel

Japan

Malaysia

Mexico

Montenegro

New Zealand

Peru

Philippines

Poland

San Marino

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering OPZELURA around the world.

Country	Patent Number	Title	Estimated Expiration
Spain	2612489
Japan	5710430
Eurasian Patent Organization	019784	СОЛИ ИНГИБИТОРА ЯНУС-КИНАЗЫ (R)-3-(4-(7H-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)-1H-ПИРАЗОЛ-1-ИЛ)-3-ЦИКЛОПЕНТИЛПРОПАННИТРИЛА (SALTS OF THE JANUS KINASE INHIBITOR (R)-3-(4-(7H-PYRROLO[2,3-d]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-3-CYCLOPENTYLPROPANENITRILE)
Mexico	346183
Australia	2011255443
Taiwan	201831490	Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as JANUS KINASE inhibitors
Hong Kong	1124840	HETEROARYL SUBSTITUTED PYRROLO[2,3-B]PYRIDINES AND PYRROLO[2,3- B]PYRIMIDINES AS JANUS KINASE INHIBITORS

Supplementary Protection Certificates for OPZELURA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1966202	300574	Netherlands		PRODUCT NAME: RUXOLITINIB OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/12/773/001-003 20120828
1966202	CR 2013 00005	Denmark		PRODUCT NAME: RUXOLITINIB, ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, HERUNDER RUXOLITINIB PHOSFAT; REG. NO/DATE: EU/1/12/773/001-003 20120823
2455382	132017000044713	Italy		PRODUCT NAME: RUXOLITINIB, O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE(JAKAVI); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/12/773/001-016, 20150313
1966202	SPC/GB13/005	United Kingdom		PRODUCT NAME: RUXOLITINIB, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF.; REGISTERED: UK EU/1/12/773/001 20120828; UK EU/1/12/773/002 20120828; UK EU/1/12/773/003 20120828
2455382	CA 2017 00018	Denmark		PRODUCT NAME: RUXOLITINIB ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, HERUNDER RUXOLITINIB FOSFAT; REG. NO/DATE: C(2015)1740/EU/1/12/773/001-016 20150313
2455382	PA2017012	Lithuania		PRODUCT NAME: RUKSOLITINIBAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/12/773/001-006 20150311
2455382	300870	Netherlands		PRODUCT NAME: RUXOLITINIB OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/12/773/001-016 20150313

OPZELURA: Patent Landscape and Investment Fundamentals

Last updated: February 19, 2026

Opzelura (ruxolitinib cream) represents a significant therapeutic advance for dermatological conditions, primarily atopic dermatitis and vitiligo. Its approval by the U.S. Food and Drug Administration (FDA) in September 2021 marked the first JAK inhibitor cream for topical use, targeting inflammatory pathways. The drug’s patent portfolio, primarily held by Incyte Corporation, is crucial to its market exclusivity and investment potential. Understanding the expiration dates, scope of claims, and ongoing legal challenges is paramount for assessing future market competition and revenue projections.

What is the current patent status of OPZELURA (ruxolitinib cream)?

The core composition of matter patents for ruxolitinib have either expired or are nearing expiration, a common lifecycle stage for established small molecules. However, Incyte has implemented a strategy of securing secondary patents covering specific formulations, methods of use, and manufacturing processes for Opzelura. These secondary patents are critical for extending market exclusivity beyond the initial composition of matter patent expiration.

Key Patents and Expiration Dates

The foundational patent for ruxolitinib, U.S. Patent No. 7,598,257, which claimed the compound itself, expired in December 2025. This patent was owned by Incyte. However, Incyte has aggressively pursued and been granted numerous additional patents related to ruxolitinib and its use in topical formulations.

• U.S. Patent No. 10,926,051: This patent, titled "Topical JAK Inhibitors," covers topical pharmaceutical compositions containing a JAK inhibitor, including ruxolitinib, and a pharmaceutically acceptable carrier. It is a critical patent for Opzelura’s topical application. This patent is listed in the FDA Orange Book [1].
• U.S. Patent No. 11,207,425: This patent, also listed in the Orange Book, relates to methods of treating dermatological conditions, including atopic dermatitis and vitiligo, using topical JAK inhibitors like ruxolitinib.
• U.S. Patent No. 11,369,603: Another Orange Book-listed patent focusing on topical pharmaceutical compositions for treating skin disorders.

The expiration dates for these secondary patents are generally later, extending protection well into the 2030s. For instance, U.S. Patent No. 10,926,051 is expected to expire in July 2037 [1]. The specific expiration dates for all Orange Book-listed patents for Opzelura can be found in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations (commonly known as the Orange Book) [1].

What is the competitive landscape for ruxolitinib cream?

The competitive landscape for ruxolitinib cream is characterized by both established and emerging therapies for atopic dermatitis and vitiligo. While Opzelura was the first topical JAK inhibitor approved for these indications, other treatments exist, and pipeline candidates are advancing.

Approved Treatments for Atopic Dermatitis

Atopic dermatitis treatment is multi-faceted, with a range of therapeutic options:

• Topical Corticosteroids: These remain a first-line treatment due to their efficacy and low cost. However, long-term use is associated with side effects like skin thinning and telangiectasias.
• Topical Calcineurin Inhibitors (TCIs): Tacrolimus (Protopic) and pimecrolimus (Elidel) offer steroid-sparing alternatives, particularly for sensitive areas.
• Systemic Therapies: For moderate to severe atopic dermatitis, systemic treatments include:
  • Biologics: Dupilumab (Dupixent), tralokinumab-ldrm (Adbry), and lebrikizumab (Ebglenifeg) target specific inflammatory pathways (IL-4, IL-13). These are significant competitors to systemic JAK inhibitors and, potentially, topical JAK inhibitors in more severe cases.
  • Systemic JAK Inhibitors: Upadacitinib (Rinvoq) and abrocitinib (Cibinqo) are oral JAK inhibitors approved for moderate to severe atopic dermatitis. These offer systemic treatment options and compete with the broader mechanism of action of JAK inhibition.

Approved Treatments for Vitiligo

Vitiligo treatment is less established, with limited approved options prior to Opzelura.

• Phototherapy: Narrowband ultraviolet B (NB-UVB) therapy is a common treatment.
• Topical Agents: While not always leading to significant repigmentation, topical corticosteroids and calcineurin inhibitors are sometimes used.
• Opzelura: Its approval represented a major breakthrough for repigmentation in nonsegmental vitiligo.

Pipeline and Emerging Therapies

The pipeline for dermatological treatments is active, with potential future competitors to Opzelura:

• Other Topical JAK Inhibitors: While Opzelura is the first, research into other topical JAK inhibitors is ongoing. Different JAK selectivity profiles could lead to variations in efficacy and safety.
• New Biologics: Continued research in understanding the inflammatory cascade of skin diseases will likely yield new biologic targets and therapies.

The primary competitive threat to Opzelura in the short to medium term comes from other JAK inhibitors, both topical and oral, and the established efficacy of biologics for atopic dermatitis. For vitiligo, Opzelura currently holds a strong position due to its first-in-class approval for repigmentation.

What are the key indications and market size for OPZELURA?

Opzelura is approved for two primary dermatological indications in the United States: atopic dermatitis and nonsegmental vitiligo. The market size for these conditions is substantial and growing, driven by increasing prevalence and patient demand for effective treatments.

Atopic Dermatitis (AD)

• Indication: Opzelura is indicated for the topical treatment of mild to moderate atopic dermatitis in patients 12 years of age and older whose disease is not adequately controlled by topical therapies or when those therapies are inadvisable.
• Market Size: Atopic dermatitis is a chronic inflammatory skin disease affecting a significant portion of the global population. Estimates vary, but in the U.S., it affects approximately 10% to 20% of children and 3% to 5% of adults [2]. This translates to millions of potential patients. The global AD market was valued at approximately $20.7 billion in 2022 and is projected to grow to over $30 billion by 2029, driven by new treatments and increasing diagnosis rates [3].

Nonsegmental Vitiligo

• Indication: Opzelura is indicated for the topical treatment of nonsegmental vitiligo in patients 12 years of age and older. This was a groundbreaking approval, as it was the first FDA-approved repigmentation therapy for this condition.
• Market Size: Vitiligo affects approximately 0.5% to 2% of the global population. In the U.S., this translates to an estimated 2 million to 5 million individuals [4]. While the prevalence is lower than AD, the unmet need for effective repigmentation therapies is high, making this a valuable, albeit smaller, market segment for Opzelura. The global vitiligo treatment market is smaller but poised for growth with the advent of novel therapies like Opzelura.

The dual indication provides Opzelura with a broader patient base and diversified revenue streams. The significant patient populations and increasing market sizes for both atopic dermatitis and vitiligo underscore the commercial potential of Opzelura.

What are the manufacturing and supply chain considerations for OPZELURA?

The manufacturing and supply chain for Opzelura are critical to ensuring consistent product availability and managing costs. As a topical formulation, it involves specific production processes and ingredient sourcing.

Manufacturing Process

The manufacturing of ruxolitinib cream involves the synthesis of the active pharmaceutical ingredient (API), ruxolitinib, and its subsequent formulation into a topical cream.

• API Synthesis: Ruxolitinib is a small molecule inhibitor of Janus kinases (JAKs). Its synthesis requires multi-step chemical processes, which are typically conducted by specialized chemical manufacturers or by the pharmaceutical company itself. Maintaining purity and consistency of the API is paramount.
• Formulation: The API is then combined with various excipients to create the cream base. These excipients include emulsifiers, thickeners, preservatives, and emollients, which are crucial for the drug's stability, texture, and skin penetration. The formulation must ensure the active ingredient is delivered effectively to the target skin layers.
• Quality Control: Rigorous quality control measures are implemented at each stage of manufacturing, from raw material testing to finished product analysis, to ensure compliance with Good Manufacturing Practices (GMP).

Supply Chain

The supply chain for Opzelura involves sourcing raw materials, manufacturing the API and finished product, packaging, and distribution to pharmacies and healthcare providers.

• Raw Material Sourcing: Key raw materials for API synthesis and cream formulation must be sourced from reliable suppliers. Geopolitical stability and the availability of these materials can impact production.
• Contract Manufacturing Organizations (CMOs): Pharmaceutical companies often utilize CMOs for specific manufacturing steps, particularly for API synthesis or final product filling and packaging. Incyte may use a network of CMOs to ensure capacity and manage risk.
• Distribution: The finished product is distributed through pharmaceutical wholesalers to hospitals, clinics, and retail pharmacies. Cold chain requirements, if any, would add complexity and cost, though topical creams typically do not have stringent temperature controls beyond standard room temperature storage.
• Regulatory Compliance: The entire supply chain must adhere to stringent regulatory requirements from bodies like the FDA, including GMP, Good Distribution Practices (GDP), and traceability mandates.

Potential Risks and Mitigation

• API Supply Disruptions: Reliance on a limited number of API suppliers can pose a risk. Diversification of suppliers and maintaining strategic inventory levels can mitigate this.
• Formulation Stability: Topical formulations can be susceptible to degradation. Robust stability testing and optimized formulation are essential.
• Intellectual Property and Generics: While secondary patents protect Opzelura, any successful challenges to these patents or the eventual expiry of key patents would open the door for generic competition, impacting supply chain dynamics and pricing.

What are the potential for generic competition and patent challenges?

The threat of generic competition is a central consideration for any pharmaceutical investment. For Opzelura, this threat is managed through Incyte’s strategy of obtaining and defending a robust portfolio of secondary patents.

Generic Entry Timeline

The expiration of the foundational composition of matter patent for ruxolitinib (U.S. Patent No. 7,598,257) in December 2025 is a significant date. However, this does not immediately open the door for generic topical formulations of ruxolitinib. The key to preventing early generic entry lies in the strength and enforceability of Incyte's secondary patents covering the topical cream formulation and methods of use.

• Secondary Patent Expirations: As noted, key patents like U.S. Patent No. 10,926,051 are not set to expire until July 2037. This provides a substantial period of market exclusivity for the branded product.
• Paragraph IV Filings: Generic manufacturers will likely attempt to challenge these secondary patents through Paragraph IV filings under the Hatch-Waxman Act. This process involves a generic company notifying the FDA that a patent listed in the Orange Book is invalid, unenforceable, or will not be infringed by its proposed generic product.
• Patent Litigation: Such challenges almost invariably lead to patent litigation. The outcome of these lawsuits is unpredictable and can significantly impact the timeline for generic entry. Incyte has a history of vigorously defending its patents.

Patent Challenges and Strategies

Incyte’s strategy to protect Opzelura involves:

• Broad Claims: Securing patents with broad claims that cover not only the specific formulation but also variations in excipients, manufacturing processes, and methods of treatment.
• Multiple Patents: Filing a layered portfolio of patents that provide overlapping protection. This means a generic company must successfully invalidate multiple patents to launch a product.
• Litigation Experience: Incyte, like many pharmaceutical companies, has extensive experience in defending its intellectual property through litigation. This includes engaging experienced patent attorneys and preparing for protracted legal battles.

The potential for generic competition is thus delayed by the strength of Incyte’s secondary patent estate. However, the ultimate expiration of these patents, or successful challenges to them, will eventually lead to generic erosion of market share, as is standard in the pharmaceutical industry. Investors must factor in the potential timing and impact of generic entry when evaluating the long-term profitability of Opzelura.

What are the financial projections and valuation considerations for OPZELURA?

The financial projections for Opzelura are driven by its approved indications, market penetration potential, pricing strategy, and the duration of its patent protection. Valuation considerations must account for R&D investment recovery, market growth, competitive pressures, and the ultimate impact of patent expiry.

Sales Performance and Projections

Opzelura's sales performance has been robust since its launch, particularly driven by its novel indication for vitiligo.

• 2022 Sales: Opzelura generated approximately $232 million in net sales in 2022, its first full year on the market [5]. This exceeded initial market expectations for its launch year.
• 2023 Sales: Incyte reported net sales of Opzelura reaching $333 million for the nine months ended September 30, 2023, indicating continued growth [6]. Full-year 2023 projections would likely place it significantly higher, potentially nearing or exceeding $450 million.
• Growth Drivers: Growth is fueled by increasing physician adoption, expanding patient access, and strong clinical data supporting efficacy in both atopic dermatitis and vitiligo. The vitiligo indication, in particular, has high unmet need and limited competition.

Pricing Strategy

The pricing of Opzelura reflects its innovative status and the significant R&D investment.

• Wholesale Acquisition Cost (WAC): The WAC for Opzelura is substantial, consistent with specialty dermatological treatments. For example, a 60g tube had a WAC of over $1,000.
• Net Price: The net price realized by Incyte after rebates and discounts to payers is lower but still significant. Pricing power is supported by its first-in-class status and the substantial clinical benefit it offers.

Valuation Considerations

Valuation models for Opzelura (and by extension, Incyte) must incorporate several key factors:

• Peak Sales Potential: Analysts project peak annual sales for Opzelura to reach between $800 million and $1.5 billion, depending on market uptake, label expansions, and competitive dynamics [7].
• Patent Exclusivity Period: The extended patent protection into the late 2030s is a major positive. The valuation should reflect projected revenues during this period of market exclusivity.
• Discount Rate: A significant discount rate should be applied to future cash flows to account for the inherent risks in pharmaceutical development, regulatory approvals, market adoption, and potential patent litigation.
• Cost of Goods Sold (COGS) and Operating Expenses: These include manufacturing costs, marketing and sales expenses, and R&D expenditures related to potential label expansions or lifecycle management.
• Generic Erosion Modeling: Projections must include a realistic model for revenue decline following the introduction of generic competition. This typically involves a sharp drop in sales and pricing.

The current valuation of Incyte Corporation (INCY) reflects the success of Opzelura and the potential of its pipeline. Investors will scrutinize the company's ability to maintain growth, defend its intellectual property, and manage the eventual transition to a more competitive market landscape.

Key Takeaways

• Opzelura’s market exclusivity is secured through a robust portfolio of secondary patents, with key formulations and methods of use protected until at least 2037.
• The drug addresses significant unmet needs in both atopic dermatitis and vitiligo, contributing to strong initial sales growth.
• While Opzelura was a first-in-class topical JAK inhibitor, competition from other JAK inhibitors and biologics, particularly in atopic dermatitis, is present and evolving.
• The financial projections for Opzelura are positive, driven by strong market demand and extended patent protection, but must account for the eventual impact of generic competition.

Frequently Asked Questions

1. When does the primary composition of matter patent for ruxolitinib expire? The primary composition of matter patent for ruxolitinib, U.S. Patent No. 7,598,257, expired in December 2025.

2. What is the significance of secondary patents for Opzelura? Secondary patents cover specific topical formulations, methods of treatment, and manufacturing processes, extending market exclusivity beyond the expiration of the original composition of matter patent.

3. How do biologics for atopic dermatitis compete with Opzelura? Biologics target specific inflammatory cytokines and are often used for moderate to severe atopic dermatitis, representing a significant treatment option for a subset of patients who might otherwise consider topical therapies or systemic JAK inhibitors.

4. What is the current sales trajectory of Opzelura? Opzelura has demonstrated strong initial sales growth, exceeding $333 million in the first nine months of 2023, indicating increasing market adoption.

5. What is the expected impact of generic competition on Opzelura sales? Generic competition is expected to significantly erode Opzelura's market share and pricing power upon its introduction, the timing of which depends on the outcomes of potential patent challenges.

Citations

[1] U.S. Food & Drug Administration. (n.d.). Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). Retrieved from [FDA website search for Opzelura (ruxolitinib cream) patents] (Note: Direct URL changes; manual search required on FDA.gov)

[2] National Eczema Association. (n.d.). Eczema Statistics. Retrieved from [National Eczema Association website]

[3] Grand View Research. (2023). Atopic Dermatitis Market Size, Share & Trends Analysis Report. (Report details specific to market size and projections).

[4] National Institute of Arthritis and Musculoskeletal and Skin Diseases. (n.d.). Vitiligo. Retrieved from [NIAMS website]

[5] Incyte Corporation. (2023, February 28). Incyte Announces Fourth Quarter and Full Year 2022 Financial Results. [Press Release].

[6] Incyte Corporation. (2023, November 2). Incyte Announces Third Quarter 2023 Financial Results. [Press Release].

[7] Pharmaceutical industry analyst reports and consensus estimates. (Various sources, 2023-2024). (Note: Specific report names and publishers are proprietary and vary; this refers to general market intelligence from reputable financial analysis firms).